))
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
Manage episode 386983633 series 2838329
Sisällön tarjoaa VJHemOnc. VJHemOnc tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who discuss the growing role of bispecific antibodies, including glofitamab, epcoritamab and odronextamab, in this disease setting.
200 jaksoa
Jaa
